PRX-03140: Phase IIb start

This quarter, Epix will begin a 3-month double-blind, U.S. Phase IIb trial in 240 patients to compare 150 and 75 mg doses of PRX-03140 to Aricept and to placebo. An additional 3-month open-label exte...